Sponsored Links

Study shows RAD001 froze kidney cancer for a year

Friday, May 16, 2008

WASHINGTON (Reuters) - Nearly two-thirds of kidney cancer patients taking Novartis AG's RAD001 had progression of their disease delayed by a year, a significantly better result than in those taking placebo, investigators said.

Read Complete Story

Recent Health News

Sponsored Links

Tools
Bookmark/Discuss